Skip to main content
Drugmakers hesitate to work on new antibiotics despite incentives

Antibiotic-resistant infections kill tens of thousands of people and cost tens of billions of dollars each year, and though scientists are developing innovative methods to fight dangerous bacteria, market forces keep many investors on the sidelines. In response, the FDA and European Medicines Agency have offered expedited approval pathways and economic incentives, public-private financing mechanisms have emerged, and venture capitalists have set up targeted funds, but few drugmakers have stepped up development efforts.

Full Story: